|
摘要：
|
|
摘要：代谢相关脂肪性肝病（metabolic associated fatty liver disease，MAFLD）是全球
常见的慢性肝病，是以肝脏脂肪堆积为基础，合并超重/肥胖、2型糖尿病或代谢紊乱的
一种代谢功能障碍性疾病。MAFLD患者因脂质代谢异常，往往与高血压、动脉粥样硬
化和急性冠脉综合征、心力衰竭等心血管疾病（cardiovascular disease，CVD）密切相
关。CVD已成为MAFLD患者肝外死亡的主要原因。但目前对MAFLD人群CVD相关风
险管理评价相对缺乏。本文对近年来MAFLD相关心脑血管不良事件筛查临床研究现状
进行综述，重点阐述MAFLD患者CVD风险评估的研究现状。
|
|
Abstract: Metabolic associated fatty liver disease (MAFLD) is a common chronic liver disease
in the world. Based on the accumulation of liver fat, MAFLD is a metabolic dysfunction disease
combined with overweight/obesity, type 2 diabetes or metabolic disorder. Because of abnormal
lipid metabolism, patients with MAFLD are often closely related to cardiovascular diseases
(CVD), such as hypertension, atherosclerosis, acute coronary syndrome, heart failure. CVD has
become the leading cause of extrahepatic death in patients with MAFLD. However, currently
there is a relative lack of CVD related risk management evaluation algorithms for MAFLD
population. This article provided a literature review of the current clinical research status of
screening for cardiovascular and cerebrovascular adverse events related to MAFLD in recent
years, with a focus on the research status of CVD risk assessment in patients with MAFLD .
|
|
基金项目：
|
|
|
|
作者简介：
|
|
|
|
参考文献：
|
|
|
|
服务与反馈：
|
|
【文章下载】【加入收藏】
|
|
|
|